Upadacitinib hemihydrate

2024年10月30日，艾伯维（NYSE：ABBV）发布2024年第三季度（报告期）财报。期内公司净收入144.6 亿美元，同比增长4.9%（按固定汇率计算，下同）。 美国市场收入111.48亿美元，国际市场（美国以外）收入33.12亿美元 报告期内公司净收入144.6 亿美元，同比增长4.9%（按固定汇率计算，下同）。其中美国市场收入111.48亿美元，国际市场（美国以外）收入33.12亿美元（+12.4%）。 按业务板块分 自免业务收入最高，达70.46亿美元，同比增长4.8%； 其次为神经系统业务，收入23.63亿美元，同比增长16.0%； 肿瘤业务收入16.87亿美元（+13.0%）； 医美板块收入12.39亿美元（+1.8%）； 眼科板块收入2.4亿美元，同比下降11.2%。 自免业务中 修美乐（阿达木单抗）受到生物类似药影响，报告期内销售额22.27亿美元，同比下降36.5%。 相比之下，Skyrizi（利生奇珠单抗）和Rinvoq（乌帕替尼）销售迅速增长，利生奇珠单抗销售额32.05亿美元，同比增长51.5%；乌帕替尼销售额16.14亿美元，同比增长47.4%。 肿瘤领域以伊布替尼居首， 报告期内伊布替尼销售额8.28亿美元，同比减少8.8%； 维奈克拉销售额6.77亿美元，同比增长18.2%； FRα ADC药物Elahere（索米妥昔单抗）销售额1.39亿美元，新型CD3/CD20双抗Epkinly（epcoritamab）销售额4300万美元。 神经系统领域中， 精神疾病药物Vraylar（卡利拉嗪）销售额8.75亿美元，同比增长16.6%； 肉毒素Botox销售额8.48亿美元，同比增长14.4%。 在神经系统领域，艾伯维持续布局，前不久收购Aliada，获得阿尔茨海默病管线ALIA-1758。 2024年前三季度，艾伯维总体收入412.32亿美元，同比增长4.1%。公司上调了全年收入指引。 全球医疗情报领导者 解锁隐藏在数据中的商业潜力  关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。 联系我们 投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写 点击阅读原文，解锁完整双语新闻

iStock, Michael Vi AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise. Despite the continued biosimilar erosion on Humira sales, AbbVie exceeded analyst expectations in its third-quarter earnings report on Wednesday, buoyed by the strong growth of its other immunology assets. AbbVie’s revenue jumped 3.8% in Q3 bringing in $14.46 billion, which was 1% ahead of the consensus forecast of $14.3 billion. The company reported adjusted diluted earnings-per-share (EPS) of $3, which also beat Wall Street’s projection of $2.94. AbbVie’s Q3 beat comes despite the steep decline in Humira sales, which cratered 37% year-over-year and dropped to $2.23 billion, compared to $3.55 billion during the same period last year. In an investor call on Wednesday, CCO Jeffrey Stuart attributed the company’s shrinking Humira business to its loss of exclusivity and “biosimilar competition,” particularly in the U.S. Still, company executives were optimistic about its immunology unit on the call, with AbbVie CEO Robert Michael saying that he is “extremely pleased” with the performance of the ex-Humira platform. “AbbVie’s diversified portfolio delivered sales that were $260 million above our expectations, Michael said, noting that “our ex-Humira platform drove this overachievement.” Skyrizi, indicated for plaque psoriasis and psoriatic arthritis and which AbbVie has positioned as a successor to Humira, surged 50.8% in Q3 with $3.2 billion in net revenue—surpassing both the analyst consensus. Rinvoq, an oral JAK inhibitor approved for ulcerative colitis, Crohn’s disease and other immune-mediated diseases, grew 45.3% in the quarter with $1.17 billion in sales. William Blair analyst Myles Minter in an investor note wrote that AbbVie’s Q3 beat “was mainly driven by continued strength of Skyrizi and Rinvoq,” adding that AbbVIe is likely looking at “strong and durable growth pro the coming years thanks to its strong growth platform.” Regarding the biosimilar challenge to Humira, Minter noted that “AbbVie has managed the erosion well,” which in turn will give investors “enough visibility to get comfortable with the strong growth outlook for AbbVie over the near and long term.” Guggenheim Partners analyst Vamil Divan pointed to AbbVie’s cancer products Imbruvica and Venclexta, which “performed better than the Street expected.” Venclexta saw nearly 15% year-over-year growth and brought in $677 million in Q3, while Imbruvica—despite earning $828 million—was hit with an 8.8% decline in sales. Looking at AbbVie’s pipeline, Leerink Partners analyst David Risinger flagged an upcoming readout for emraclidine, a potentially best-in-class next-generation anti-psychotic drug being developed for schizophrenia. Data from two Phase II studies—EMPOWER-1 and EMPOWER-2—are expected by the end of the year . Risinger also called out two “Alzheimer’s wildcards,” ABBV-552 and AL002, both of which are in Phase II.